Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 105

    1.

    Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.

    Andersson C, Weeke P, Brendorp B, Køber L, Fosbøl EL, Sharma AM, Finer N, Caterson ID, Rode RA, James PT, Torp-Pedersen C.

    Nutr Metab (Lond). 2009 Oct 14;6:42.

    PMID:
    19828038
    [PubMed - in process]
    Free PMC Article
    2.

    The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period.

    Weeke P, Andersson C, Fosbøl EL, Brendorp B, Køber L, Sharma AM, Finer N, James PT, Caterson ID, Rode RA, Torp-Pedersen C.

    BMC Endocr Disord. 2010 Feb 26;10:3.

    PMID:
    20184783
    [PubMed]
    Free PMC Article
    3.

    [Pharmacological therapy of obesity].

    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

    G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

    PMID:
    18773755
    [PubMed - indexed for MEDLINE]
    4.

    Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).

    Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP; SCOUT Investigators.

    Diabetes Obes Metab. 2009 Mar;11(3):239-50. Epub 2008 Jul 29.

    PMID:
    18671798
    [PubMed - indexed for MEDLINE]
    5.

    Final Report on Carcinogens Background Document for Styrene.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.

    PMID:
    20737009
    [PubMed - as supplied by publisher]
    6.

    Final Report on Carcinogens Background Document for Formaldehyde.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.

    PMID:
    20737003
    [PubMed - as supplied by publisher]
    7.

    Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial.

    Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C; SCOUT Executive Steering Committee; SCOUT investigators.

    Metabolism. 2009 Aug;58(8):1109-15. Epub 2009 Jun 18.

    PMID:
    19454355
    [PubMed - indexed for MEDLINE]
    8.

    Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.

    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.

    Diabetes Obes Metab. 2000 Apr;2(2):105-12.

    PMID:
    11220522
    [PubMed - indexed for MEDLINE]
    9.

    Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.

    Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.

    Clin Ther. 2004 Sep;26(9):1427-35.

    PMID:
    15531005
    [PubMed - indexed for MEDLINE]
    10.

    Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

    James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators.

    N Engl J Med. 2010 Sep 2;363(10):905-17.

    PMID:
    20818901
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.

    McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD.

    Arch Intern Med. 2000 Jul 24;160(14):2185-91.

    PMID:
    10904462
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.

    Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP; on behalf of the SCOUT Investigators.

    Diabetes Obes Metab. 2011 Dec 22. doi: 10.1111/j.1463-1326.2011.01554.x. [Epub ahead of print]

    PMID:
    22192338
    [PubMed - as supplied by publisher]
    13.

    Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus.

    Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP; Sibutramine/Diabetes Clinical Study Group.

    Diabetes Obes Metab. 2000 Jun;2(3):175-87.

    PMID:
    11220553
    [PubMed - indexed for MEDLINE]
    14.

    Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.

    Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P; SCOUT Investigators.

    Eur Heart J. 2007 Dec;28(23):2915-23. Epub 2007 Jun 26.

    PMID:
    17595194
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.

    Kaukua JK, Pekkarinen TA, Rissanen AM.

    Int J Obes Relat Metab Disord. 2004 Apr;28(4):600-5.

    PMID:
    14770192
    [PubMed - indexed for MEDLINE]
    16.

    Gender differences in cardiovascular risk factors in obese, nondiabetic first degree relatives of African Americans with type 2 diabetes mellitus.

    Gaillard TR, Schuster DP, Osei K.

    Ethn Dis. 1998 Autumn;8(3):319-30.

    PMID:
    9926902
    [PubMed - indexed for MEDLINE]
    17.

    Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study.

    Ong G, Davis WA, Davis TM.

    Diabetologia. 2010 Jul;53(7):1288-94. Epub 2010 Mar 30.

    PMID:
    20349345
    [PubMed - indexed for MEDLINE]
    18.

    Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period.

    Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Torp-Pedersen C, Sharma AM, Ge H, Santoro D, Shepherd G, James P; SCOUT Investigators.

    Obesity (Silver Spring). 2010 May;18(5):987-94. Epub 2009 Oct 8. Erratum in: Obesity (Silver Spring). 2010 May;18(5):1063.

    PMID:
    19816415
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    The obese older female patient: CV risk and the SCOUT study.

    Coutinho WF.

    Int J Obes (Lond). 2007 Nov;31 Suppl 2:S26-30; discussion S31-2.

    PMID:
    17968434
    [PubMed - indexed for MEDLINE]
    20.

    Cardiovascular risk-benefit profile of sibutramine.

    Scheen AJ.

    Am J Cardiovasc Drugs. 2010;10(5):321-34. doi: 10.2165/11584800-000000000-00000. Review.

    PMID:
    20860415
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk